ABOUT US
TenNor Therapeutics specializes in research and development of new drugs for the treatment of digestive diseases ...[More]
NEWS
-
TenNor Therapeutics Announces $25 Million Series B Financing to Advance TNP-2092 Clinical Trials
-
TenNor’s Publication on TNP-2092 was Selected as ACS Editors’ Choice
-
TenNor Releases TNP-2092 Information during ASM Microbe 2016 Conference
-
TenNor Publishes Dual-Acting Antibacterial Agent TNP-2092
-
TenNor Therapeutics Received Government Grant to Support Development of Dual-Action Molecules for the Treatment of MDR/XDR-TB
-
TenNor Participates and Presents in the 10th Chinese H. pylori and Digestive Diseases Forum
-
NIH Guests Visited TenNor Therapeutics
-
TenNor Therapeutics Attended The 9th Chinese H. pylori and Digestive Diseases Forum
-
Global Antibiotic Pipeline
-
Human-Hp Mismatch Boosts Stomach Cancer